EUSARNAD
Joint European and South African Research Network in Anxiety Disorders
| Coordinatore | UNIVERSITY OF SOUTHAMPTON
Organization address
address: Highfield contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 289˙800 € |
| EC contributo | 289˙800 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2010-IRSES |
| Funding Scheme | MC-IRSES |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-10-01 - 2015-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITY OF SOUTHAMPTON
Organization address
address: Highfield contact info |
UK (SOUTHAMPTON) | coordinator | 46˙200.00 |
| 2 |
ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
NL (LEIDEN) | participant | 42˙000.00 |
| 3 |
THE UNIVERSITY OF HERTFORDSHIRE HIGHER EDUCATION CORPORATION
Organization address
address: COLLEGE LANE contact info |
UK (HATFIELD) | participant | 33˙600.00 |
| 4 |
TARTU ULIKOOL
Organization address
address: ULIKOOLI 18 contact info |
EE (TARTU) | participant | 25˙200.00 |
| 5 |
GOETEBORGS UNIVERSITET
Organization address
address: VASAPARKEN contact info |
SE (GOETEBORG) | participant | 21˙000.00 |
| 6 |
UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT
Organization address
address: JOSEF-SCHNEIDER-STRASSE 2 contact info |
DE (WUERZBURG) | participant | 21˙000.00 |
| 7 |
UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS
Organization address
address: Robert-Koch-Strasse 40 contact info |
DE (GOETTINGEN) | participant | 21˙000.00 |
| 8 |
UPPSALA UNIVERSITET
Organization address
address: SANKT OLOFSGATAN 10 B contact info |
SE (UPPSALA) | participant | 21˙000.00 |
| 9 |
UNIVERSIDAD DE CANTABRIA
Organization address
address: AVENIDA DE LOS CASTROS S/N contact info |
ES (SANTANDER) | participant | 16˙800.00 |
| 10 |
UNIVERSITA DEGLI STUDI DI MILANO
Organization address
address: Via Festa Del Perdono 7 contact info |
IT (MILANO) | participant | 16˙800.00 |
| 11 |
UNIVERSITY OF BRISTOL
Organization address
address: TYNDALL AVENUE SENATE HOUSE contact info |
UK (BRISTOL) | participant | 16˙800.00 |
| 12 |
MEDICAL RESEARCH INFRASTRUCTURE DEVELOPMENT AND HEALTH SERVICES FUND BY THE SHEBA MEDICAL CENTER
Organization address
address: TEL HASHOMER SHEBA MEDICAL CENTER contact info |
IL (RAMAT GAN) | participant | 8˙400.00 |
| 13 |
ACADEMISCH ZIEKENHUIS GRONINGEN
Organization address
address: Hanzeplein 1 contact info |
NL (GRONINGEN) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The overall aim of our proposal is to build on the strengths of an existing European network for research into causes and maintaining factors in anxiety disorders and to extend these by establishing firmer research collaboration with the University of Cape Town in South Africa. Through establishing this research exchange, we aim to share knowledge and expertise among participating centres, and ensure a comprehensive translational research approach in anxiety disorders, relevant to the needs of developed and developing societies.
The exchange scheme has three broad objectives. First, to develop a collaborative international database for the detailed characterisation of large samples of patients, across the range of anxiety disorders. Second, to provide exchange researchers with a range of complementary training opportunities, gaining experience in innovative investigations in anxiety disorders. These opportunities include characterisation of differing endophenotypes across diagnoses; using neuroimaging, genetic polymorphism and other techniques to bridge the gap between preclinical and clinical studies; and identifying predictors of clinical outcome and treatment response using dimensional and other approaches. Third, to establish a firm platform to support subsequent pragmatic randomised effectiveness trials in patients who have not responded to previous treatment interventions.
The value of the scheme is in its capacity to facilitate access to additional and larger clinical populations, to include centres of research excellence across many countries, and to share the knowledge and expertise of leading researchers with long-standing and wide-ranging interests in anxiety disorders. Furthermore, the training opportunities within the scheme would increase the knowledge and skills of the ‘next generation’ of anxiety disorder researchers and thereby contribute to efforts to meet the challenges imposed by these common, burdensome and costly medical conditions.'